Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461386 | 0.86 | MELK (0.42) | MELKALDH1A1HPGDMAPTGAA | |
| SCHEMBL4468184 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HPGDMAPTGAAPOLB | |
| SCHEMBL4475765 | 0.79 | ALDH1A1 (0.65) | MELKALDH1A1HPGDMAPTGAA | |
| SCHEMBL4487980 | 0.78 | ALDH1A1 (0.43) | MELKALDH1A1HPGDMAPTGAA | |
| SCHEMBL4469960 | 0.78 | ALDH1A1 (0.47) | MELKALDH1A1HPGDMAPTGAA | |
| SCHEMBL4471658 | 0.77 | MAPT (0.57) | MELKALDH1A1HPGDMAPTGAA | |
| SCHEMBL4510386 | 0.77 | HPGD (0.39) | MELKALDH1A1HPGDMAPTGAA | |
| SCHEMBL3823495 | 0.76 | MAPT (0.68) | MELKALDH1A1HPGDMAPTGAA | |
| SCHEMBL4473330 | 0.76 | MELK (0.70) | MELKALDH1A1HPGDMAPTGAA | |
| SCHEMBL4476324 | 0.76 | ALDH1A1 (0.58) | MELKALDH1A1HPGDMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470821-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585859-B2 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1742627-A4 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON INC (US) | 2009-08-26 | — | — | EP | disclosed |
| CN-101031293-A | Pde4b inhibitors and uses therefor | PLEXXIKON INC (US) | 2007-09-05 | — | — | CN | disclosed |
| EP-1742627-A2 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006078287-A9 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON INC (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006078287-A2 | PDE4B INHIBITORS AND USES THEREFOR | PLEXXIKON, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PLEXXIKON, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286793-A1 | PDE4B INHIBITORS AND USES THEREFOR | PDE4B, PDE7B, PDE4A | MELK 3735/4885ALDH1A1 802/4885HPGD 319/4885 |
| US-20060041006-A1 | PDE4B inhibitors and uses therefor | PDE4B, PDE7B, PDE4A | MELK 3735/4885ALDH1A1 802/4885HPGD 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.